A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Latest Information Update: 27 Jan 2022
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Labrys Biologics; Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 23 May 2020 Results (n=2503) assessing relationships between differences in fremanezumab exposure resulting from monthly and quarterly dosing schedules and efficacy endpoints of the phase 2 and 3 clinical trials for fremanezumab by developing E-R models, published in the Headache.
- 18 Nov 2018 Results of post-hoc analyses assessing the efficacy of each dose during the first 3 weeks of treatment, published in the Headache.
- 17 Aug 2018 Results published in the Neurology